QLQX adjunct therapy reduced cardiovascular death by 18% (RR 0.82) and hospitalization for heart failure by 22% (RR 0.78) in patients with HFrEF.
Does Qiliqiangxin capsule adjunctive therapy reduce cardiovascular events and improve cardiac function in patients with HFrEF compared to conventional treatments alone?
Qiliqiangxin capsule added to conventional therapy significantly reduces cardiovascular death and heart failure hospitalizations while improving cardiac function in patients with HFrEF.
Tasa de eventos absoluta: 0% vs 0%
ETHNOPHARMACOLOGICAL RELEVANCE: The Qiliqiangxin (QLQX) capsule is a prominent traditional Chinese medicine formulation developed based on the collateral disease theory, specifically for the treatment of heart failure (HF). Its composition includes 11 medicinal botanicals, such as Huang Qi, Ren Shen, and Dan Shen, and is designed to tonify qi, activate blood circulation, and promote diuresis. Supported by over 20 years of extensive clinical application, modern pharmacological research, and stringent quality control, QLQX has been incorporated into the national heart failure guidelines in China. AIM OF THE STUDY: This study evaluates the efficacy and safety of QLQX as adjunctive therapy for heart failure with reduced ejection fraction (HFrEF). METHODS: We systematically searched seven databases until February 24, 2025, for randomized controlled trials (RCTs) evaluating QLQX in patients with HFrEF. Two independent researchers screened trials, extracted data, and assessed the risk of bias using the Cochrane RoB 2.0 tool. Meta-analyses were conducted for efficacy and safety outcomes, with evidence quality evaluated through the GRADE framework. RESULTS: Twenty-four RCTs (n = 5580) were included. Compared with conventional treatments (CTs) alone, QLQX adjunctive therapy significantly reduced the risk of cardiovascular death (RR = 0.82, 95 %CI 0.69, 0.96, P = 0.02), hospitalization for HF (RR = 0.78, 95 %CI 0.67, 0.91, P = 0.001), and composite cardiovascular events by 18 % (RR = 0.82, 95 %CI 0.73, 0.92, P = 0.0005), with evidence quality rated as moderate. QLQX significantly improved cardiac function parameters compared to controls: increased left ventricular ejection fraction (MD = 7.14, 95 % CI 6.75, 7.54, P < 0.05), reduced left ventricular end-diastolic diameter (MD = -5.25, 95 % CI -5.75, -4.75, P < 0.05), improved NYHA class (RR = 1.19, 95 %CI 1.14, 1.25), decreased NT-proBNP (SMD = -2.01, 95 %CI -2.26, -1.95, P < 0.05), and increased 6-min walking distance (MD = 44.80, 95 %CI 42.37, 47.22, P < 0.05). CONCLUSION: QLQX adjunct therapy effectively reduces cardiovascular death and HF hospitalization while improving cardiac function in HFrEF, with favorable safety. Large-scale multicenter RCTs with extended follow-up are required to confirm long-term benefits and address existing study limitations.
Li et al. (Thu,) reported a other. QLQX adjunct therapy reduced cardiovascular death by 18% (RR 0.82) and hospitalization for heart failure by 22% (RR 0.78) in patients with HFrEF.